Canadian vehicle sales declined 8.2% in February amid EV market ‘collapse': DesRosiers
New-vehicle sales in Canada fell close to 10 per cent in February, driven in part by a 'stunning' decline in battery-electric vehicle sales and a record comparable month last year, according to DesRosiers Automotive Consultants (DAC).
Despite the year-over-year slide, DAC Managing Partner Andrew King said estimated February sales of 122,000 vehicles was 'solid.' Monthly sales figures are estimates because most automakers report only on a quarterly basis. Ford only reports annually.
'While a decline of 8.2 per cent sounds concerning, it should be remembered that February 2024 was easily the strongest February of all time — as finally a plentiful supply of vehicles was available after 30 months of shortages,' King said.
Sign up for the Automotive News Canada Daily to get the top news of the day in your inbox each business weekday afternoon.
Toyota recorded the biggest February decline among manufacturers that report monthly, with sales falling nearly 25 per cent year over year to 11,660 vehicles, according to the Automotive News Research & Data Center in Detroit.
Sales dropped 10.9 per cent at Kia; 6.4 per cent at Honda; 4.3 per cent at Volvo Cars; and 1.8 per cent at Subaru.
Hyundai, meantime, stayed ahead of its pace last year, with sales of 9,200 topping February 2024 by 6.5 per cent.
Mazda also bucked the downward trend, thanks mainly to strong sales of its CX-50. The company sold 988 of the compact crossovers in February, close to double the 546 it sold a year earlier. Relatively small declines in sales of the CX-30 and CX-5 were offset by comparable gains by the Mazda 3 and CX-90. Across its entire lineup, the brand sold 4,559 vehicles in February, up 11.9 per cent from the same month a year earlier.
Unlike the relative steadiness of the overall market, EV sales faced an 'astonishing' collapse during the second month of 2025, DAC said.
After the chaotic end to the federal Incentives for Zero-Emission Vehicles program in January and a pause to Quebec's rebate program, February was the first full month that EV buyers in Canada lacked access to either incentive.
'Stunning declines were witnessed by a plethora of BEVs, as sales plummeted across the segment,' DAC said.
According to the Automotive News Research & Data Center, exclusively electric models experienced sales declines of as much as 85 per cent in February.
Hyundai's Ioniq 5 and 6 posted year-over-year declines of 37.9 per cent and 81.4 per cent, respectively, in February. Toyota BZ4x sales slid 73.2 per cent to 107 vehicles from 399. And sales of the Kia EV5 declined 85.8 per cent to 65 vehicles from 457 last February.
The dramatic decline in EV sales extends the negative trend in January flagged by S&P Global Mobility, when the federal and Quebec rebates were still in play for a portion of the month.
While the February sales total signals a 'healthy' auto retail market in Canada, with the seasonally adjusted annual rate coming it at two million vehicles, tariffs threaten to upend the momentum, DAC said.
American tariffs of 25 per cent on most imports from Canada and Mexico came into force at 12:01 a.m. March 4. President Donald Trump issued a one-month exemption for automotive 36 hours later, but further U.S. tariffs on imports of steel and aluminum are expected March 12, as well as global reciprocal tariffs in April.
The Canadian government's response could also influence sales. Ottawa retaliated to Trump's salvo immediately with 25-per-cent tariffs on $30 billion worth of U.S. goods. A second tranche of retaliatory tariffs on $125 billion of U.S. imports, likely to include vehicles and auto parts, will kick in if U.S. tariffs return April 2.
'Whether we will see another month in 2025 reach a SAAR of two million depends greatly upon how the tariff situation unfolds,' DAC said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
2 hours ago
- Yahoo
The Hashemite Kingdom of Jordan Announces New Ocean Innovation Hub in Partnership with Innovative Blue Technology Company Voyacy Regen
Located in the Gulf of Aqaba, in the Hashemite Kingdom of Jordan, the Aqaba Marine Park will focus on building climate-resilient coastal marine infrastructure at an unprecedented scale NICE, France, June 10, 2025 /PRNewswire/ -- Today, His Majesty King Abdullah II ibn Al Hussein announced a new partnership with blue technology company Voyacy Regen, cofounded by Philippe and Ashlan Cousteau, to build a new ocean technology accelerator and innovation hub in Aqaba, Jordan. Under the Aqaba Marine Park (AMP) initiative, this groundbreaking project will focus on regenerating coral reefs and critical coastal marine infrastructure at scale to create a climate-resilient world where people and the ocean can thrive. "Today's announcement marks a pivotal step forward in our effort to embed sustainable practices and climate actions as an integral part of Jordan's economic growth, while establishing safeguards that will protect the kingdom's environment and natural resources for future generations," said Hussein Al-Safadi, CEO of Aqaba Development Corporation (ADC). "The Aqaba Marine Park will play a vital role in regenerating coral reefs, strengthening climate resilience, and promoting the sustainable use of ocean resources, in alignment with His Majesty King Abdullah II's vision for Aqaba, and with the guidance and support of the AMP's International Honorary Advisory Board." Coral reefs absorb up to 97% of storm surge and are critical barriers against increasingly catastrophic storms that already cause billions of dollars of damage and threaten millions of lives. However, coral reefs are disappearing at an alarming rate – it's estimated that half of the world's corals have disappeared since the 1950s, with 14% vanishing between 2009 and 2018 alone. "This partnership with the Hashemite Kingdom of Jordan is deeply meaningful to me, and I am honored to be working with His Majesty King Abdullah II," said Philippe Cousteau, Co-founder of Voyacy Regen and Aqaba Marine Park International Honorary Advisory Board Member. "Coastal communities are on the front lines of our rapidly changing world, and we couldn't think of a better partner than Jordan to scale the tangible solutions we need to solve this crisis." Located within the Aqaba Marine Nature Reserve, under ASEZA's supervision, and home to one of the Red Sea's most vibrant coral reefs and marine ecosystems, the Aqaba Marine Park, in cooperation with Voyacy, will focus on large-scale coral reef regeneration and coastal marine infrastructure to help create a climate-resilient future where both people and the ocean can thrive. Traditional methods of coral restoration, which involve growing small batches of corals and planting manually, cannot be implemented at the scale and speed needed to meet this crisis. Utilizing Voyacy's approaches, the Innovation Hub in Aqaba represents a nexus of action that will see the development and implementation of new, best-in-class technologies. The core technology combines 3D-printed reef structures, designed to absorb wave energy, with aquacultured heat-tolerant corals and AI technology. This allows for the rapid and cost-effective deployment of infrastructure that can protect coastal communities against destructive storms while promoting biodiversity. Voyacy and Jordan have mobilized a coral propagation farm and deployed a best-in-class commercial-scale 3D printer in Aqaba to accelerate this technology. About the Aqaba Development CorporationThe Aqaba Development Corporation (ADC) is the government's investment arm for Aqaba Special Economic Zone (ASEZ), owning and managing key assets including ports, airport, and land. ADC drives sustainable growth by enabling investment and infrastructure across six priority sectors: tourism, manufacturing, green energy, logistics, creative industries, and education, and leads multiple initiative to support the blue economy. About the Aqaba Special Economic Zone (ASEZA)Launched in 2001, the Aqaba Special Economic Zone (ASEZA) is designed and developed to embody and emphasize His Majesty King Abdullah II's vision for Aqaba. The Royal Vision is committed to transforming Aqaba into a world-class business hub and leisure destination, while putting the community's welfare and preserving the city's environmental and cultural heritage at heart. As Aqaba's transformation plans were set in motion, over the past 24 years, enormous milestones were achieved by mobilizing the Zone's government institutions, community, and the private sector. About Voyacy RegenFounded by Philippe and Ashlan Cousteau, Voyacy Regen is a pioneering blue tech company that combines human ingenuity, breakthrough technology, and innovative partnerships to solve one of the biggest problems facing coastal communities around the world; the collapse of the natural ocean systems that protect us. Voyacy's core technology combines 3D-printed reef structures, designed to absorb wave energy, with aquacultured heat-tolerant corals and AI technology, resulting in a commercially viable solution that will protect coastal communities, build the blue economy, and increase biodiversity. Learn more: For further information contact: cousteau@ Info@ SOURCE Voyacy Regen Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
4 hours ago
- Miami Herald
Kia EV5 GT Spotted Testing In Korea
If Hyundai has its N performance vehicle family, Kia answers with its GT badge, especially on its burgeoning line of electric vehicles. The Korean marque already offers the EV6 GT and EV9 GT, both topping their respective ranges with outstanding performance. Even the US-bound Kia EV3 is rumored to receive a high-performance GT version. We also know that the EV5, which sits right below the EV6, is getting the GT treatment. While its design may have been leaked in China last year, a prototype has already been spotted on the road, thanks to Shorts Car on Instagram, signaling an imminent official debut. Even through the camo, there are clues. The EV5 GT prototype wears a set of sporty alloy wheels that bear a strong resemblance to those on the EV6 GT. Yellow brake calipers peek through the spokes, hinting at upgraded stopping power, while a wider stance and lower ride height suggest revised suspension tuning and stickier rubber underneath. In typical GT fashion, the visual changes are purposeful, not just cosmetic. Stylistically, the EV5 GT will borrow heavily from Kia's latest EV design playbook. Think EV6 and EV9, but with added aggression unique to the GT family. Unlike the EV6, the EV5 GT will have a boxy body, closely resembling the EV9. Unlike China's EV5, the GT model is based on the global version, which means revisions aimed at broader markets. Chief among them is a redesigned center console, replacing the less conventional jump seat setup with a more premium, practical armrest. Official details of what's under the EV5 GT's skin are still scarce, but the EV6 GT should set a benchmark at 576 hp and a 0-62 mph time of 3.5 seconds. It's unclear if the EV5 GT will have the same output, but a dual-motor, all-wheel-drive setup is almost certain at this point. Inside reports point to using an 82 kWh nickel-cobalt-manganese battery, with a projected range between 373 and 435 miles. The Kia EV5 GT will be produced in China and Korea, so it's unlikely to reach the U.S. market, at least for now. If the automaker introduces it stateside, local production is expected in hopes of curbing the current tariffs imposed on imported vehicles and parts. Copyright 2025 The Arena Group, Inc. All Rights Reserved.